APFID

Home > Latest News on ID > Infectious Disease News
LOGIN
Relapse of Infections Is the Most Challenging Aspect of Treating Clostridium difficile Infections in the Hospital Setting
Date: 2009-10-01   Read: 95561

Relapse of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting

Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting. Surveyed infectious disease specialists emphasize the need for new agents that have lower relapse rates than the current standard-of-care. Currently, clinicians have limited treatment options for patients with this infection; oral metronidazole and oral vancomycin are the most commonly used agents for treating both first and relapse episodes of C. difficile infections in the United States and Europe.

In the new report entitled Hospital Anti-Infectives Insight Series: Clostridium Difficile, surveyed infectious disease specialists indicate that new strains of C. difficile and the lack of effective second- and later-line therapies are also significant challenges in treatment. C. difficile is a gram-positive bacterium that can cause symptoms ranging from severe diarrhea to life-threatening inflammation of the colon. A new hypervirulent strain, BI/NAP1/027, has been associated with severe outbreaks of C. difficile in North America and Europe, and has raised awareness about the need for improved treatment and prevention strategies for this infection.

"C. difficile infections represent a growing area of concern due to the increased incidence of these infections and a limited number of treatment options," stated Lisa Arias, analyst at Decision Resources. "Surveyed physicians would like to see novel therapies that have a lower recurrence rate than current agents."

****************************************************************************

Adapted from materials provided by Medical News TODAY



Next Wyeth Receives Positive Opinion from European Regulators for Its 13-valent Pneumococcal Candidate Vaccine for Infants & Young Children 2009-10-01 90153
Previous Hospital Infections Cost $1 Billion In Lost Bed Days 2009-10-01 95744
޴ٷΰ ΰ